Dana-Farber Cancer Institute
Avatar

Study of Abemaciclib for Patients with RB-Positive, Triple Negative Metastatic Breast Cancer

By Dana-Farber Cancer Institute FEATURING Shom Goel
April 1, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi

Featured Video

22:25
Novartis Oncology

The Importance of Dosing and Patient Adherence in HR+/HER2- mBC

Feat. N. McAndrew

Related Content

AUTOPLAY
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
28:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
13:03
Novartis Oncology

CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…

Feat. D. Slamon
04:28
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …

Feat. S. Tolaney
24:36
ESMO 2022 Conference Coverage

ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates

Feat. H. Rugo, J. O'Shaughnessy
23:58
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
03:05
ecancer

ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…

Feat. D. Slamon
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
03:32
UCSF School of Medicine

Management of Abemaciclib-Related Diarrhea in HR+/HER2- eBC

Feat. S. Donahue
16:08
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Tailoring Post-Neoadjuvant Therapy in TNB…

Feat. H. Han
09:32
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…

Feat. S. Tolaney
10:22
ESMO 2022 Conference Coverage

ESMO 2022 Updates on mTNBC

Feat. L. Carey
07:49
ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients…

Feat. H. Rugo
26:03
Total Health

HR+ mBC: Optimizing Endocrine Therapy

Feat. J. O'Shaughnessy
19:05
International Congress on Cancer Metastasis

Could We Cure Metastatic Breast Cancer?

Feat. L. Pusztai